Monoclonal antibodies are produced using a technique called hybridoma technology. This involves fusing a specific type of immune cell with a cancer cell, resulting in a cell line that can produce large quantities of a single type of antibody indefinitely. The generated antibodies are then purified and tested for their efficacy and safety.
